Twenty-four-hour energy balance in Crohn disease patients: metabolic implications of steroid treatment.
Several hypotheses have been proposed to explain the nutritional deficiencies seen in Crohn disease patients, including inadequate food intake, decreased assimilation and increased loss of nutrients, and increased energy expenditure. To assess the effect of steroid therapy on body composition, energy expenditure, and fuel selection in Crohn disease, we compared 12 patients (6 men and 6 women) with biopsy-proven ileal Crohn disease with 11 healthy volunteers (6 men and 5 women). Five patients [Crohn's disease activity index (CDAI) = 98.4 +/- 3.78] took no medication and seven patients (CDAI = 283.9 +/- 22.5) were administered 29 +/- 18 mg prednisone/d. Body composition was evaluated by isotopic dilution and bioelectrical impedance analysis, and 24-h energy expenditure and basal metabolic rate were measured in a respiratory chamber. Fat-free mass was not significantly different among groups, whereas fat mass was lower in patients than in control subjects. Energy intake was higher in treated patients than in both untreated patients (P = 0.004) and control subjects (P = 0.005). Fecal losses were not significantly different between untreated patients and control subjects, but were higher (and proportional to the CDAI) in treated patients than in control subjects (P = 0.001). Metabolizable energy was not significantly different among groups, whereas energy balance was significantly higher in treated patients than in both control subjects (P = 0.0057) and untreated patients (P = 0.018). Nitrogen balance was mildly negative in treated patients compared with both control subjects and untreated patients, but not significantly so. In conclusion, prednisone treatment in Crohn disease patients stimulates food intake, promoting an overall positive energy balance despite large fecal nutrient losses.
Mingrone
G
G
Istituto di Medicina Interna, Università Cattolica del Sacro Cuore, Rome, Italy. iclcm@rm.unicatt.it
Benedetti
G
G
Capristo
E
E
De Gaetano
A
A
Greco
A V
AV
Tataranni
P A
PA
Gasbarrini
G
G
D000328:Adult; D001823:Body Composition / Q000187:drug effects; D002940:Circadian Rhythm; D015331:Cohort Studies; D003424:Crohn Disease / Q000188:drug therapy / Q000378:metabolism*; D004435:Eating / Q000187:drug effects; D017097:Electric Impedance; D002149:Energy Intake / Q000187:drug effects; D004734:Energy Metabolism / Q000187:drug effects / Q000502:physiology*; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009584:Nitrogen / Q000378:metabolism*; D009752:Nutritional Status; D011241:Prednisone / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D005938:Glucocorticoids; D009584:Nitrogen; D011241:Prednisone